With the increasing emphasis on precision medicine, most discussion of diabetes has focused on heterogeneity in type 2 diabetes and distinguishing T2D from monogenic diabetes or atypical forms of diabetes, with the assumption that one can accurately define T1D based on the clinical phenotype. However, this view has been substantially altered by two major changes: T1D begins with evidence of islet-directed autoimmunity prior to appearance of dysglycemia or hyperglycemia and that T1D likely results from different pathways to β cell destruction as reflected by differences in age of onset, genetics, pancreas pathology, metabolism, insulin secretion, and ultimately by differences in response to therapies and diabetes-related complications.
At this one day symposium, which is divided into two sessions: Pre-diabetic heterogeneity and Post-diagnosis heterogeneity; national and international basic and clinical researchers within T1D research will present data on endotypes in T1D-autoimmunity, discuss rapid and slow progressors from autoimmunity to T1D onset. Further data on residual β-cell function after diagnosis will be presented and an update on responders versus non-responders in Immunotherapy Intervention in T1D will close the symposium, which is open for all interested in T1D research.
Date: 29 October 2021
Time: 9:30 – 16:45
Venue: Medicon Valley Alliance – Edvard Thomsens Vej 14, Ørestad, København S
WHO CAN ATTEND
This symposium is intended clinical and basic researchers in Denmark and southern Sweden with an interest in the subject.
The participants are selected on a first come, first served basis.
Please note, that you are not guaranteed a seat at the symposium if you do not meet the target group requirements. Priority is given to participants employed at Danish or Swedish research and health institutions or in the life science industry. If the event is overbooked, the DDA reserves its right to select participants based on the defined requirements and country of employment.
See the tentative program here.
– Caroline Brorsson, Postdoc, University of Copenhagen (DK)
– Flemming Pociot, Professor, Steno Diabetes Center Copenhagen (DK)
– Jesper Johannesen, Professor, Herlev – Gentofte Hospital (DK)
– Petra Pöllänen, MD, PhD, University of Helsinki (FI)
– Åke Lernmark, Principal Investigator, Lund University (SE)
Flemming Pociot, Professor, Steno Diabetes Center Copenhagen (DK)
Jesper Johannesen, Professor, Herlev – Gentofte Hospital (DK)
The symposium is organised in collaboration with DiaUnion.
The vision of DiaUnion is to gather the strong research skills within screening, genetics and immunology in type 1 diabetes and related autoimmune diseases, in a transnational Danish-Swedish power center with the ultimative goal: a cure for type 1 diabetes. In DiaUnion 1.0 feasibility studies for establishing a screening program (DiaUnion 2.0) is being conducted as a basis for advanced prevention and intervention studies (DiaUnion 3.0).